Alessandro Santin, MD < Yale School of ...

Dr. Alessandro Santin

Claim this profile

Smilow Cancer Hospital at Yale New Haven

Studies Ovarian Cancer
Studies Endometrial Cancer
17 reported clinical trials
25 drugs studied

Area of expertise

1Ovarian Cancer
Alessandro Santin has run 8 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
FRα positive
Stage III
2Endometrial Cancer
Alessandro Santin has run 6 trials for Endometrial Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
Smilow Cancer Hospital At Yale-New Haven
Image of trial facility.
Yale University School Of Medicine

Clinical Trials Alessandro Santin is currently running

Image of trial facility.

Avutometinib + Defactinib

for Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3

More about Alessandro Santin

Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Alessandro Santin has experience with
  • Carboplatin
  • Paclitaxel
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Topotecan
  • Mirvetuximab Soravtansine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Alessandro Santin specialize in?
Is Alessandro Santin currently recruiting for clinical trials?
Are there any treatments that Alessandro Santin has studied deeply?
What is the best way to schedule an appointment with Alessandro Santin?
What is the office address of Alessandro Santin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security